Should consumers enjoy less legal protection if they take a generic drug instead of a brand name? The U.S. Supreme Court may answer that once and for all.
Tonight at 7 on the Philadelphia CNN-News affiliate WFMZ-TV, The American Law Journal presents "Are Generic Drug Manufacturers Getting a Free Pass?" Host Christopher Naughton welcomes plaintiffs attorney Claudine Q. Homolash of Sheller P.C., commercial litigator Terry M. Henry of Blank Rome, anesthesiologist Paul Langevin of Hahnemann University Hospital and research fellow and lecturer for Seton Hall Law’s Center for Health and Pharmaceutical Law and Policy, professor Kate Greenwood. The panel looks at U.S. Supreme Court cases (Pliva v. Mensing, the recent Mutual Pharmaceutical v. Bartlett) and beyond (Alabama’s Wyeth v. Weeks).
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
